Annabelle Brough is a Manager at CBPartners
Connect with Annabelle Brough
The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.
CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.
There have been several notable standout features in the 2020 NRDL including an update which saw manufacturer applications allowed for the first time compared to prior updates.
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.
The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.
Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.
In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS. CBPartners' European Center of Excellence discusses the benefits of early engagement with NICE for both manufacturers and patients alike.
